Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLX NASDAQ:GMAB NYSE:QGEN NYSE:RDY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$70.50-0.9%$67.52$47.86▼$107.37$3.89B0.28446,817 shs867,672 shsGMABGenmab A/S$21.43-5.6%$21.74$17.24▼$27.94$13.75B0.951.08 million shs1.75 million shsQGENQIAGEN$48.02-0.7%$48.02$37.63▼$51.88$10.68B0.641.69 million shs1.29 million shsRDYDr. Reddy's Laboratories$13.82+1.6%$14.85$12.26▼$16.89$11.52B0.291.53 million shs1.11 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx-0.91%-0.90%+2.17%+22.04%+38.48%GMABGenmab A/S-5.55%-1.61%-0.70%+10.52%-19.01%QGENQIAGEN-0.62%-3.77%-0.02%+14.69%+11.12%RDYDr. Reddy's Laboratories+1.47%-0.97%-6.34%+2.94%-16.48%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACLXArcellx2.5956 of 5 stars3.62.00.00.03.32.50.0GMABGenmab A/S3.7068 of 5 stars3.33.00.00.03.90.03.1QGENQIAGEN3.5569 of 5 stars1.12.01.74.52.61.71.9RDYDr. Reddy's Laboratories2.3722 of 5 stars2.52.01.70.02.90.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 3.13Buy$114.3162.14% UpsideGMABGenmab A/S 2.64Moderate Buy$37.8076.39% UpsideQGENQIAGEN 2.27Hold$49.693.47% UpsideRDYDr. Reddy's Laboratories 3.00Buy$16.9522.69% UpsideCurrent Analyst Ratings BreakdownLatest ACLX, GMAB, RDY, and QGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/7/2025QGENQIAGENCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold8/7/2025QGENQIAGENUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$48.00 ➝ $50.008/4/2025ACLXArcellxCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/31/2025ACLXArcellxScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$93.00 ➝ $133.007/8/2025GMABGenmab A/STruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$45.00 ➝ $46.006/26/2025QGENQIAGENBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$50.00 ➝ $53.006/24/2025QGENQIAGENBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$55.006/17/2025ACLXArcellxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$110.006/16/2025ACLXArcellxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$115.006/5/2025RDYDr. Reddy's LaboratoriesHsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/5/2025RDYDr. Reddy's LaboratoriesHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$14.44 ➝ $16.90(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$107.94M35.99N/AN/A$8.41 per share8.38GMABGenmab A/S$3.12B4.40$1.52 per share14.13$8.04 per share2.67QGENQIAGEN$1.98B5.40$3.20 per share14.99$16.05 per share2.99RDYDr. Reddy's Laboratories$3.81B3.03$1.03 per share13.36$4.94 per share2.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$107.35M-$2.990.00N/AN/A-329.93%-41.63%-26.55%8/14/2025 (Estimated)GMABGenmab A/S$1.14B$1.7612.5312.046.5137.53%21.23%17.06%N/AQGENQIAGEN$83.59M$1.6928.3719.522.4518.30%14.77%8.86%N/ARDYDr. Reddy's Laboratories$663M$0.6620.9316.855.5216.99%17.25%11.63%N/ALatest ACLX, GMAB, RDY, and QGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ACLXArcellx-$1.03-$0.94+$0.09-$0.94$16.76 million$7.55 million8/7/2025Q2 2025GMABGenmab A/S$0.39$0.54+$0.15$0.54$5.77 billion$925.00 million8/5/2025Q2 2025QGENQIAGEN$0.60$0.60N/A$0.44$523.97 million$533.54 million7/23/2025Q1 25/26RDYDr. Reddy's Laboratories$0.18$0.20+$0.02$0.20$88.27 billion$988.82 million5/9/2025Q4 24/25RDYDr. Reddy's Laboratories$0.20$0.22+$0.02$0.22$83.70 billion$996.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AGMABGenmab A/SN/AN/AN/AN/AN/AQGENQIAGEN$0.250.52%N/A14.79%N/ARDYDr. Reddy's Laboratories$0.070.51%N/A10.61%N/ALatest ACLX, GMAB, RDY, and QGEN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/1/2025QGENQIAGEN$0.250.52%7/2/20257/3/20257/10/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A4.934.93GMABGenmab A/SN/A5.345.32QGENQIAGEN0.403.372.83RDYDr. Reddy's Laboratories0.011.891.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%GMABGenmab A/S7.07%QGENQIAGEN70.00%RDYDr. Reddy's Laboratories3.85%Insider OwnershipCompanyInsider OwnershipACLXArcellx8.35%GMABGenmab A/S1.54%QGENQIAGEN9.00%RDYDr. Reddy's Laboratories2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8055.11 million50.51 millionOptionableGMABGenmab A/S2,682641.54 million631.66 millionOptionableQGENQIAGEN5,765222.29 million202.29 millionOptionableRDYDr. Reddy's Laboratories27,811834.90 million818.20 millionOptionableACLX, GMAB, RDY, and QGEN HeadlinesRecent News About These CompaniesXY Capital Ltd Sells 47,520 Shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY)August 9 at 6:47 AM | marketbeat.comUS Bancorp DE Has $2.15 Million Holdings in Dr. Reddy's Laboratories Ltd (NYSE:RDY)August 9 at 3:47 AM | marketbeat.comPinpoint Asset Management Ltd Reduces Position in Dr. Reddy's Laboratories Ltd (NYSE:RDY)August 8 at 7:56 AM | marketbeat.comEnvestnet Asset Management Inc. Cuts Stock Holdings in Dr. Reddy's Laboratories Ltd (NYSE:RDY)August 7 at 3:05 AM | marketbeat.comDr. Reddy's: Needs To Invest $0.95 To Produce $1 Of New RevenuesAugust 4, 2025 | seekingalpha.comComparing Dr. Reddy's Laboratories (NYSE:RDY) and Acura Pharmaceuticals (OTCMKTS:ACUR)August 2, 2025 | americanbankingnews.comDr. Reddy's Laboratories Ltd (NYSE:RDY) Shares Sold by Allianz Asset Management GmbHJuly 29, 2025 | marketbeat.comDr. Reddy’s Laboratories Releases Q1 2025 Earnings Call AudioJuly 25, 2025 | theglobeandmail.comDr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost RevenuesJuly 24, 2025 | zacks.comDr. Reddy's Laboratories Limited (RDY) Q1 2026 Earnings Call TranscriptJuly 23, 2025 | seekingalpha.comDr. Reddy's Laboratories Limited 2026 Q1 - Results - Earnings Call PresentationJuly 23, 2025 | seekingalpha.comDr. Reddy's Q1FY26 Financial ResultsJuly 23, 2025 | businesswire.comDr. Reddy’s to launch generic semaglutide in 87 countries: BloombergJuly 23, 2025 | msn.comDr. Reddy’s Laboratories (RDY) and Alvotech Enter Into a Collaboration and License AgreementJuly 23, 2025 | msn.comCerity Partners LLC Buys 88,628 Shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY)July 20, 2025 | marketbeat.comCenterBook Partners LP Makes New Investment in Dr. Reddy's Laboratories Ltd (NYSE:RDY)July 19, 2025 | marketbeat.comDr. Reddy's Laboratories Ltd (NYSE:RDY) Shares Sold by Migdal Insurance & Financial Holdings Ltd.July 19, 2025 | marketbeat.comNew Strong Sell Stocks for July 18thJuly 18, 2025 | zacks.comDr. Reddy's Laboratories (RDY) Expected to Announce Earnings on FridayJuly 18, 2025 | marketbeat.comDr. Reddy's Laboratories climbs Thursday, underperforms competitorsJuly 17, 2025 | marketwatch.comDr. Reddy’s Laboratories Ltd. (DRREDDY) Has a New Rating from Morgan StanleyJuly 16, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACLX, GMAB, RDY, and QGEN Company DescriptionsArcellx NASDAQ:ACLX$70.50 -0.65 (-0.91%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$70.48 -0.02 (-0.02%) As of 08/8/2025 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Genmab A/S NASDAQ:GMAB$21.43 -1.26 (-5.55%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$22.42 +0.99 (+4.62%) As of 08/8/2025 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.QIAGEN NYSE:QGEN$48.02 -0.34 (-0.70%) Closing price 08/8/2025 03:59 PM EasternExtended Trading$48.00 -0.02 (-0.03%) As of 08/8/2025 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.Dr. Reddy's Laboratories NYSE:RDY$13.82 +0.22 (+1.58%) Closing price 08/8/2025 03:59 PM EasternExtended Trading$13.80 -0.01 (-0.07%) As of 08/8/2025 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact? Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
